AngioDynamics has announced the receipt of new CPT Category I codes by the American Medical Association’s CPT Editorial Panel for the treatment of lesions in the prostate and liver using its NanoKnife System.
The decision is expected to streamline reimbursement for healthcare providers conducting irreversible electroporation (IRE) ablation procedures.
Go deeper with GlobalData
Effective from 1 January 2026, these codes will attach physician relative value units.
AngioDynamics explained that the NanoKnife System employs IRE technology to destroy cells in a minimally invasive manner, without thermal energy.
High-voltage pulses create permanent nanopores within cell membranes, offering advantages over traditional surgery or thermal ablation techniques due to its precision and preservation of surrounding tissues, the US medtech added.
With the establishment of these new codes, healthcare providers can bill more accurately for treatments administered.
This development is anticipated to lead to wider insurance coverage and defined reimbursement rates for NanoKnife procedures, potentially increasing market access to this technology.
AngioDynamics president and CEO Jim Clemmer said: “Achieving CPT Category I status is a significant milestone for the NanoKnife System and underscores our commitment to providing innovative and effective treatment options for patients.
Clemmer added: “This achievement highlights the value of AngioDynamics’ strategic investments in our innovative NanoKnife System and IRE technology. With CPT Category I codes now established for prostate and liver lesions, we will continue to work to expand patient access to these life-changing treatments.”
CPT Category I codes are allocated to services and procedures that are clinically effective, commonly used, and recognised as valuable in the medical community.
The inclusion of IRE under these codes follows extensive clinical studies and peer-reviewed data affirming the efficacy of the NanoKnife System, the company noted.
Last month, AngioDynamics commenced a trial of the AlphaVac F1885 thrombectomy system for treating patients with acute pulmonary embolism.
The system, which received CE marking and FDA clearance, features a funnel cannula design for non-surgical, manual blood clot removal.
